---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-015507"
form_type: "8-K"
ticker: "SNDX"
cik: "0001395937"
company_name: "Syndax Pharmaceuticals Inc"
filed_at: "2022-08-08T23:59:59+00:00"
generated_at: "2026-06-24T02:41:41.336570+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Syndax Q2 net loss $37.6M ($0.62/sh); on track for pivotal data in 1H23

## Summary
- Cash $378.9M; net loss $37.6M ($0.62/sh) vs $22.9M ($0.44/sh) year ago.
- R&D expenses $29.7M (up from $16.9M); G&A $8.0M (up from $5.8M).
- On track to report topline data from revumenib and axatilimab pivotal programs in 1H23.
- Updated revumenib Phase 1 data expected 4Q22; axatilimab IPF trial start in 4Q22.
- Appointed Keith A. Goldan as CFO in June 2022.

## SEC filing metadata
- accession: 0000950170-22-015507
- form_type: 8-K
- ticker: SNDX
- cik: 0001395937
- company_name: Syndax Pharmaceuticals Inc
- filed_at: 2022-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1395937/000095017022015507/0000950170-22-015507-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1395937/000095017022015507/sndx-20220808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-015507
- JSON: https://secwatch.observer/filing/0000950170-22-015507.json
- Plain text: https://secwatch.observer/filing/0000950170-22-015507.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.